The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 3
  • 1
    Abercrombie, Ian
    Ceo born in June 1961
    Individual (3 offsprings)
    Officer
    2022-02-02 ~ now
    OF - director → CIF 0
  • 2
    Hanna, Wilfred Sydney
    Company Director born in April 1967
    Individual (17 offsprings)
    Officer
    2019-10-01 ~ now
    OF - director → CIF 0
  • 3
    NUCANA BIOPHARMACEUTICALS LIMITED - 2008-07-02
    NUCANA LIMITED - 2006-11-02
    DUNWILCO (1277) LIMITED - 2005-10-14
    1, Lochrin Square, 92-98 Fountainbridge, Edinburgh, Scotland
    Corporate (5 parents, 1 offspring)
    Equity (Company account)
    301,379 GBP2023-09-30
    Person with significant control
    2019-10-01 ~ now
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
Ceased 1
  • Quinn, Martin Alexander
    Solicitor born in March 1970
    Individual (16 offsprings)
    Officer
    2016-10-07 ~ 2019-10-01
    OF - director → CIF 0
    Mr Martin Alexander Quinn
    Born in March 1970
    Individual (16 offsprings)
    Person with significant control
    2016-10-07 ~ 2019-10-01
    PE - Ownership of shares – 75% or moreCIF 0
parent relation
Company in focus

ATEN THERAPEUTICS LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Debtors
7,033 GBP2023-09-30
16,410 GBP2022-09-30
Cash at bank and in hand
27,376 GBP2023-09-30
41,886 GBP2022-09-30
Current Assets
34,409 GBP2023-09-30
58,296 GBP2022-09-30
Creditors
Current, Amounts falling due within one year
-180,060 GBP2023-09-30
-104,484 GBP2022-09-30
Net Current Assets/Liabilities
-145,651 GBP2023-09-30
-46,188 GBP2022-09-30
Equity
Called up share capital
1 GBP2023-09-30
1 GBP2022-09-30
Retained earnings (accumulated losses)
-145,652 GBP2023-09-30
-46,189 GBP2022-09-30
Equity
-145,651 GBP2023-09-30
-46,188 GBP2022-09-30
Average Number of Employees
02022-10-01 ~ 2023-09-30
02021-11-01 ~ 2022-09-30
Other Debtors
Amounts falling due within one year
7,033 GBP2023-09-30
16,410 GBP2022-09-30
Trade Creditors/Trade Payables
Current
77,239 GBP2023-09-30
34,440 GBP2022-09-30
Amounts owed to group undertakings
Current
94,581 GBP2023-09-30
70,000 GBP2022-09-30
Other Creditors
Current
8,240 GBP2023-09-30
44 GBP2022-09-30
Creditors
Current
180,060 GBP2023-09-30
104,484 GBP2022-09-30

  • ATEN THERAPEUTICS LTD
    Info
    Registered number SC547221
    1 Lochrin Square, 92-98 Fountainbridge, Edinburgh EH3 9QA
    Private Limited Company incorporated on 2016-10-07 (8 years 8 months). The company status is Active.
    The last date of confirmation statement was made at 2024-10-16
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.
© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.